AVALGLUCOSIDASE ALFA (Nexviadyme®)
Clinical Indication
Pompe disease
Comments
In line with NICE TA821. This product should be used by specialist centres only. At the time of classification LLR is not a site of a specialist centre
Date of classification
October 2022
Do not prescribe
Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.